The US drug regulator issued a Form 483 with four observations after an August 6-14 inspection of Dr Reddy’s Bachupally formulations facility. The company said it will respond within the stipulated timeline.
The US drug regulator issued a Form 483 with four observations after an August 6-14 inspection of Dr Reddy’s Bachupally formulations facility. The company said it will respond within the stipulated timeline.